推荐产品
等級
certified reference material
品質等級
形狀
liquid
特點
Snap-N-Spike®/Snap-N-Shoot®
包裝
ampule of 1 mL
製造商／商標名
Cerilliant®
濃度
1.0 mg/mL in methanol
技術
gas chromatography (GC): suitable
liquid chromatography (LC): suitable
應用
forensics and toxicology
形式
single component solution
儲存溫度
2-8°C
SMILES 字串
OC1=C(O2)C([C@]([C@@H]2[C@H](O)CC3)(CCN4CC5CC5)[C@]3(O)[C@H]4C6)=C6C=C1
InChI
1S/C20H25NO4/c22-13-4-3-12-9-15-20(24)6-5-14(23)18-19(20,16(12)17(13)25-18)7-8-21(15)10-11-1-2-11/h3-4,11,14-15,18,22-24H,1-2,5-10H2/t14-,15-,18+,19+,20-/m1/s1
InChI 密鑰
JLVNEHKORQFVQJ-PYIJOLGTSA-N
一般說明
6ß-Naltrexol is the primary urinary metabolite of Naltrexone, an opiate sold under the trade names Revia, Depade, and Vivitrol® and used primarily in the management of alcohol or opiate dependence. This analytical reference standard is appropriate for use in LC/MS or GC/MS applications from clinical toxicology and forensic analysis to urine drug testing.
應用
- Advanced analytical techniques for pharmacokinetics: The development of a rapid and sensitive gas chromatography-mass spectrometry method for nalmefene quantification in human plasma, pivotal for pharmacokinetic studies, underscores the importance of 6β-Naltrexol in therapeutic drug monitoring and addiction treatment research (Xie et al., 2002).
法律資訊
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Vivitrol is a registered trademark of Alkermes, Inc.
相關產品
产品编号
说明
价格
訊號詞
Danger
危險分類
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
標靶器官
Eyes
儲存類別代碼
3 - Flammable liquids
水污染物質分類（WGK）
WGK 1
閃點（°F）
49.5 °F - closed cup
閃點（°C）
9.7 °C - closed cup
Stan L Banks et al.
Pharmaceutical research, 25(7), 1677-1685 (2008-05-02)
The purpose of this investigation was to evaluate the in vitro microneedle (MN) enhanced percutaneous absorption of naltrexone hydrochloride salt (NTX x HCl) compared to naltrexone base (NTX) in hairless guinea pig skin (GP) and human abdominal skin. In a
Waleed O Farid et al.
PloS one, 7(12), e52812-e52812 (2013-01-10)
Naltrexone is not recommended during pregnancy. However, sustained-release naltrexone implant use in humans has resulted in cases of inadvertent foetal exposure. Here, we used clinically relevant dosing to examine the effects of maternally administered sustained-release naltrexone on the rat brain
Mary F Divin et al.
European journal of pharmacology, 583(1), 48-55 (2008-02-16)
It has been proposed that on chronic morphine treatment the micro-opioid receptor becomes constitutively active, and as a consequence, the opioid withdrawal response arises from a reduction in the level of this constitutively active receptor. In support of this, the
Ling-Di Yan et al.
Yao xue xue bao = Acta pharmaceutica Sinica, 44(7), 722-725 (2009-10-08)
The pharmacokinetics of 6beta-naltrexol (6beta-NOL) following single intramuscular administration and multiple intramuscular injection once per day for seven days was studied in 4 Beagle dogs. Plasma concentration of 6beta-NOL in dogs was analyzed by a combination of high performance liquid
David J Martin et al.
Bioorganic & medicinal chemistry letters, 22(22), 6801-6805 (2012-07-10)
In an effort to better understand the conformational preferences that inform the biological activity of naltrexone and related naltrexol derivatives, a new synthesis of the restricted analog 3-OBn-6β,14-epoxymorphinan 4 is described. 4 was synthesized starting from naltrexone in 50% overall
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门